Latest news with #EU4
Yahoo
2 days ago
- Business
- Yahoo
INBRIJA Positioned for Stronger Market Penetration as Demand Grows for Inhaled Parkinson's Therapy
INBRIJA, a dopamine replacement therapy for off periods in Parkinson's disease, holds significant market potential due to its ability to provide rapid relief from motor symptoms. With the increasing prevalence of Parkinson's globally, the demand for effective treatments is growing. INBRIJA offers a novel, non-oral alternative, positioning it well in the market for patients who struggle with traditional therapies. LAS VEGAS, May 29, 2025 /PRNewswire/ -- DelveInsight's "INBRIJA Market Size, Forecast, and Market Insight Report" highlights the details around INBRIJA, which consists of a dry powder formulation of levodopa for oral inhalation with the INBRIJA inhaler. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of INBRIJA. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Acorda Therapeutics' INBRIJA (Levodopa) Overview INBRIJA is an inhalable dry powder formulation of levodopa designed for use with the INBRIJA inhaler. The medication is delivered via white hypromellose capsules, each containing 42 mg of levodopa in a spray-dried powder form, along with excipients such as 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and sodium chloride. Levodopa, the active ingredient in INBRIJA, is an aromatic amino acid with the chemical name (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid. Its molecular formula is C₉H₁₁NO₄, and it has a molecular weight of 197.19 g/mol. INBRIJA is indicated for the intermittent relief of OFF episodes in patients with Parkinson's disease who are already receiving treatment with carbidopa/levodopa. It is not intended to replace regular carbidopa/levodopa therapy but is used to reduce OFF periods and improve motor symptoms. Each therapeutic capsule is used with a specially designed plastic inhaler featuring a blue body, blue cap, and a white mouthpiece. Patients may use INBRIJA up to five times per day, with the maximum daily dose limited to 420 mg. Drug Name INBRIJA (Levodopa) Developer Acorda Therapeutics Approval Year 2018 (US); 2019 (EU) Primary Indication Parkinson's disease Mechanism of action Dopamine receptor agonist Route of administration Oral inhalation Learn more about INBRIJA projected market size for Parkinson's disease @ INBRIJA Market Potential Parkinson's disease is a chronic and progressive neurological condition that primarily affects the ability to control movement. It is caused by the gradual loss of dopamine-producing neurons in the brain, particularly in the substantia nigra—a region vital for regulating voluntary muscle activity. According to DelveInsight, there were approximately 3 million diagnosed prevalent cases of Parkinson's disease across the 7MM in 2024, with the United States accounting for about 45% of these. Although there is currently no cure, symptom management involves a mix of medications and supportive therapies. Treatment typically includes physical, occupational, and speech therapy, and certain patients may benefit from surgical interventions. Complementary therapies are also sometimes used to help manage specific symptoms. Commonly used drugs for Parkinson's include levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2A receptor antagonists. These medications primarily aim to alleviate motor symptoms, which significantly impact patients' quality of life. DelveInsight estimates the Parkinson's disease market in the 7MM to have been worth USD 3.5 billion in 2024. DelveInsight's analysis forecasts market growth due to the introduction of emerging therapies, expecting a rise in market size during the study period (2020–2034). The anticipated increase in market size is driven by advancements in treatment options, greater healthcare access, and a rising prevalence of the condition, which together foster higher demand for innovative and effective therapies. Discover more about the Parkinson's disease market in detail @ Parkinson's Disease Market Report Emerging Competitors of INBRIJA Some of the emerging competitors to INBRIJA in the Parkinson's disease treatment landscape include Solengepras (Cerevance), Buntanetap (Annovis Bio), Prasinezumab (Roche/Protherna), JOTROL (Jupiter Neurosciences), Glovadalen (UCB Biopharma), and others. In April 2025, Cerevance reported that the pivotal Phase III ARISE trial evaluating Solengepras as an adjunctive treatment for Parkinson's disease was ongoing, with topline results expected in the first half of 2026. Cerevance's GPR6 antagonist, Solengepras, did not meet its primary endpoint in the Phase II ASCEND trial as a monotherapy for early, untreated Parkinson's disease patients, demonstrating only a modest and statistically non-significant improvement compared to placebo, as reported at AD/PD 2025. According to the results presented at AD/PD 2025, Buntanetap has been shown to prevent cognitive decline across the entire treated ITT population. In patients with existing cognitive impairment, it improved cognitive performance along with MDS-UPDRS, WAIS, and CGI-S scores. A meeting with the US FDA to discuss the future development strategy is scheduled for the second Quarter of 2025. The ATLANTIS Phase II trial design for glovadalen was presented at AD/PD 2025, highlighting its potential as a Parkinson's treatment. As a D1PAM, it boosts dopamine signaling without directly activating receptors. To know more about the number of competing drugs in development, visit @ INBRIJA Market Positioning Compared to Other Drugs Key Milestones of INBRIJA In March 2023, Acorda Therapeutics announced that Esteve Pharmaceuticals launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain. Esteve launched INBRIJA in Germany in mid-2022. In September 2019, Acorda Therapeutics announced that the European Commission (EC) granted marketing authorization for INBRIJA 33 mg inhalation powder, hard capsules. In Europe, INBRIJA is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor. The Marketing Authorization approves INBRIJA for use in the 28 countries of the European Union, as well as Iceland, Norway, and Liechtenstein. In December 2018, INBRIJA was approved by the US FDA for intermittent treatment of OFF Episodes in people with Parkinson's taking carbidopa/levodopa. Discover how INBRIJA is shaping the Parkinson's disease treatment landscape @ INBRIJA Inhaler INBRIJA Market Dynamics INBRIJA is a medication used to manage "off" periods in patients with Parkinson's disease who are on a stable regimen of oral levodopa. The market dynamics surrounding INBRIJA are influenced by several factors, including the growing demand for innovative treatments for Parkinson's disease, an aging global population, and the increasing recognition of the importance of managing off periods in patients with Parkinson's. As the number of Parkinson's disease patients continues to rise globally, particularly with the aging Baby Boomer generation, the market for Parkinson's disease therapies is expanding, offering significant growth potential for medications like INBRIJA. One of the key drivers for INBRIJA's market is the unmet need for effective treatments for off periods. Traditional oral levodopa, the mainstay of Parkinson's treatment, can lose efficacy over time, leading to motor fluctuations that result in off periods, during which patients experience a worsening of symptoms such as tremors and rigidity. INBRIJA provides an alternative in the form of an inhaled levodopa treatment that acts rapidly to help manage these periods, offering patients a faster-acting option compared to oral medications. This positioning appeals to both patients and healthcare providers who are looking for ways to improve the quality of life for people with Parkinson's. Despite its promising potential, INBRIJA faces challenges in the market. The primary hurdle is its relatively high cost compared to traditional levodopa treatments, which could limit its accessibility, particularly in regions with limited healthcare resources. Additionally, the need for an inhaler device and potential issues related to device handling and patient compliance could also impact market penetration. Moreover, INBRIJA competes with other therapeutic options in the Parkinson's space, including dopamine agonists and other adjunctive treatments, which means ongoing education and marketing efforts are required to differentiate its unique benefits. In terms of market opportunities, INBRIJA could benefit from increased awareness among healthcare providers about the drug's role in improving patient outcomes during off periods. Collaborations with Parkinson's disease advocacy groups and patient education initiatives could help drive adoption. Furthermore, expanding indications or seeking approval for additional uses could open up new revenue streams and bolster INBRIJA's position in the Parkinson's treatment market. Overall, while the market for INBRIJA faces challenges, the growing demand for better management of Parkinson's symptoms presents opportunities for continued growth and adoption. Dive deeper to get more insight into INBRIJA's strengths & weaknesses relative to competitors @ INBRIJA Market Drug Report Table of Contents 1 Report Introduction 2 INBRIJA: Acorda Therapeutics 2.1 Product Overview 2.2 Other Development Activities 2.3 Clinical Development 2.4 Clinical Trials Information 2.5 Safety and Efficacy 2.6 Product Profile 2.7 Market Assessment 2.7.1 The 7MM Analysis 2.7.1.1 Cost Assumptions and Rebate 2.7.1.2 Pricing Trends 2.7.1.3 Analogue Assessment 2.7.1.4 Launch Year and Therapy Uptake 2.7.2 The United States Market Analysis 2.7.3 EU4 and the United Kingdom Market Analysis 2.7.3.1 Germany 2.7.3.2 France 2.7.3.3 Italy 2.7.3.4 Spain 2.7.3.5 UK 2.7.4 Japan Market Analysis 2.8 Market Drivers 2.9 Market Barriers 2.10 SWOT Analysis 3 Key Cross of Marketed Competitors of INBRIJA 4 Key Cross of Emerging Competitors of INBRIJA Related Reports Parkinson's Disease Market Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, Cerevance, among others. Parkinson's Disease Pipeline Parkinson's Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson's disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., among others. Cell and Gene Therapy in Parkinson's Disease Market Cell and Gene Therapy in Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cell and gene therapy in Parkinson's disease companies including MeiraGTx, Hope Biosciences, Sumitomo Pharma, Prevail Therapeutics, BlueRock Therapeutics, Voyager Therapeutics, among others. Parkinson's Disease Psychosis Market Parkinson's Disease Psychosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease psychosis companies, including Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences Ltd, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Sign in to access your portfolio
Globe and Mail
3 days ago
- Business
- Globe and Mail
Noonan Syndrome Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes
DelveInsight's 'Noonan Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Noonan Syndrome, historical and forecasted epidemiology as well as the Noonan Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Noonan Syndrome, offering comprehensive insights into the Noonan Syndrome revenue trends, prevalence, and treatment landscape. The report delves into key Noonan Syndrome statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Noonan Syndrome therapies. Additionally, we cover the landscape of Noonan Syndrome clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Noonan Syndrome treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Noonan Syndrome space. Some of the key facts of the Noonan Syndrome Market Report: The Noonan Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032) In May 2025, Novo Nordisk's once-weekly Sogroya (somapacitan) demonstrated non-inferiority compared to the once-daily growth hormone Norditropin (somatropin) in a Phase III trial focused on pediatric growth disorders. The Danish company reported that Sogroya enhanced the annual growth rate in pre-pubertal children born small for gestational age (SGA), those with Noonan syndrome (NS), or those with idiopathic short stature (ISS), as shown in the Phase III REAL8 basket study (NCT05330325). Key Noonan Syndrome Companies: Sanofi, Novo Nordisk A/S, BioMarin Pharmaceutical, and others Key Noonan Syndrome Therapies: MAXOMAT ®, somatropin, Vosoritide Injection, and others The Noonan Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Noonan Syndrome pipeline products will significantly revolutionize the Noonan Syndrome market dynamics. The prevalence of Noonan Syndrome Occurs in approximately 1 in 1,000 to 2,500 live births worldwide Noonan Syndrome is One of the more common genetic syndromes affecting multiple systems Noonan Syndrome Affects males and females equally, with no significant gender bias Caused by mutations in genes involved in the RAS/MAPK pathway, including PTPN11, SOS1, RAF1, and others About 50% of cases are due to mutations in the PTPN11 gene Noonan Syndrome Overview Noonan Syndrome is a genetic disorder that affects multiple parts of the body. It is characterized by distinctive facial features, short stature, heart defects (such as pulmonary valve stenosis), developmental delays, and other health issues. The condition is caused by mutations in genes involved in the RAS/MAPK signaling pathway, which plays a key role in cell growth and development. Noonan Syndrome occurs in both males and females and varies widely in severity. Early diagnosis and management can help address the associated complications and improve quality of life. Get a Free sample for the Noonan Syndrome Market Forecast, Size & Share Analysis Report: Noonan Syndrome Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Noonan Syndrome Epidemiology Segmentation: The Noonan Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalence of Noonan Syndrome Prevalent Cases of Noonan Syndrome by severity Gender-specific Prevalence of Noonan Syndrome Diagnosed Cases of Episodic and Chronic Noonan Syndrome Download the report to understand which factors are driving Noonan Syndrome epidemiology trends @ Noonan Syndrome Epidemiology Forecast Noonan Syndrome Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Noonan Syndrome market or expected to get launched during the study period. The analysis covers Noonan Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Noonan Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Noonan Syndrome Therapies and Key Companies Discover more about therapies set to grab major Noonan Syndrome market share @ Noonan Syndrome Treatment Landscape Noonan Syndrome Market Drivers Rising Diagnosis Rates Advancements in Genetic Research Pharmaceutical Collaborations Government Initiatives Noonan Syndrome Market Barriers Lack of Approved Therapies High Treatment Costs Limited Awareness Genetic Heterogeneity Scope of the Noonan Syndrome Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Noonan Syndrome Companies: Sanofi, Novo Nordisk A/S, BioMarin Pharmaceutical, and others Key Noonan Syndrome Therapies: MAXOMAT ®, somatropin, Vosoritide Injection, and others Noonan Syndrome Therapeutic Assessment: Noonan Syndrome current marketed and Noonan Syndrome emerging therapies Noonan Syndrome Market Dynamics: Noonan Syndrome market drivers and Noonan Syndrome market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Noonan Syndrome Unmet Needs, KOL's views, Analyst's views, Noonan Syndrome Market Access and Reimbursement Table of Contents 1. Noonan Syndrome Market Report Introduction 2. Executive Summary for Noonan Syndrome 3. SWOT analysis of Noonan Syndrome 4. Noonan Syndrome Patient Share (%) Overview at a Glance 5. Noonan Syndrome Market Overview at a Glance 6. Noonan Syndrome Disease Background and Overview 7. Noonan Syndrome Epidemiology and Patient Population 8. Country-Specific Patient Population of Noonan Syndrome 9. Noonan Syndrome Current Treatment and Medical Practices 10. Noonan Syndrome Unmet Needs 11. Noonan Syndrome Emerging Therapies 12. Noonan Syndrome Market Outlook 13. Country-Wise Noonan Syndrome Market Analysis (2019–2032) 14. Noonan Syndrome Market Access and Reimbursement of Therapies 15. Noonan Syndrome Market Drivers 16. Noonan Syndrome Market Barriers 17. Noonan Syndrome Appendix 18. Noonan Syndrome Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
4 days ago
- Business
- Yahoo
FILSPARI to Transform Kidney Disease Care with Its Revolutionary Treatment Approach
FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers seek disease-modifying options, FILSPARI is well-positioned to capture substantial market share, especially with favorable long-term data. LAS VEGAS, May 27, 2025 /PRNewswire/ -- DelveInsight's "FILSPARI Market Size, Forecast, and Market Insight Report" highlights the details around FILSPARI, the first and only oral, once-daily, non-immunosuppressive therapy approved in both the US and Europe for IgAN. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of FILSPARI. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Travere Therapeutics' FILSPARI (sparsentan) Overview FILSPARI (sparsentan) is a once-daily oral treatment that uniquely targets two key pathways, endothelin-1 and angiotensin II (also known as DEARA), in the progression of IgA nephropathy. It is the first approved non-immunosuppressive therapy for this condition. Endothelin-1 and angiotensin II contribute to kidney function decline by promoting inflammation and fibrosis, altering podocyte structure, causing podocyte loss, and increasing the permeability of the glomerular filtration barrier. Additionally, both are vasoconstrictors that narrow blood vessels and raise pressure in the glomeruli. The drug received accelerated approval based on its ability to reduce proteinuria. Due to potential safety concerns, it is distributed under the FILSPARI Risk Evaluation and Mitigation Strategy (REMS) program. In Europe, it is marketed by CSL Vifor, and in Japan by Renalys Pharma. Results from the registration-enabling study are expected in the second half of 2025. Drug Name FILSPARI (sparsentan) Molecule type Small molecule Developer Travere Therapeutics Primary Indication Immunoglobulin A nephropathy FILSPARI MoA ETAR antagonist; AT1R antagonist Route of administration Oral Learn more about FILSPARI projected market size for IgAN @ FILSPARI IgA Nephropathy IgA nephropathy (IgAN) is an autoimmune disorder that disrupts kidney function by damaging the small blood vessels responsible for filtration. This damage is caused by an abnormal protein that harms the glomeruli, the kidneys' main filtering units. According to DelveInsight, there were approximately 415,000 diagnosed prevalent cases of IgAN across the seven major markets in 2024, and this number is projected to grow at a CAGR of 0.6% through 2034. Current standard care involves the use of ACE inhibitors and angiotensin II receptor blockers (ARBs), primarily to manage associated symptoms like hypertension. Currently, only a few drugs have been approved for IgAN treatment, including VANRAFIA (Atrasentan) and FABHALTA (Iptacopan) by Novartis, FILSPARI (Sparsentan) by Travere Therapeutics, and TARPEYO/KINPEYGO (budesonide) by Asahi Kasei (Calliditas Therapeutics), among others. The treatment landscape is expected to undergo major changes between 2024 and 2034, driven by the introduction of innovative therapies. DelveInsight estimates the IgAN market across the seven key regions was valued at around USD 730 million in 2024 and is projected to grow at a strong CAGR of 30.5% from 2025 to 2034. With targeted treatment options for IgAN only recently emerging and a pressing need for therapies that can delay progression to end-stage kidney disease (ESKD), significant advancements in this area are likely to profoundly reshape the market in the coming years. Discover more about the IgAN market in detail @ IgA Nephropathy Market Assessment Emerging Competitors of FILSPARI Key companies advancing therapies for IgA nephropathy include Novartis (Zigakibart/FUB523), F. Hoffmann-La Roche and Ionis Pharmaceuticals (Sefaxersen/RG6299/IONIS-FB-LRx), AstraZeneca's Alexion Pharmaceuticals (ULTOMIRIS), Vera Therapeutics (Atacicept), Vertex Pharmaceuticals (Povetacicept), Otsuka Pharmaceutical (Sibeprenlimab), Biogen (Felzartamab), Arrowhead Pharmaceuticals (ARO-C3), NovelMed (NM8074), Q32 Bio (ADX-097), Walden Biosciences (WAL0921), and Takeda Pharmaceutical (TAK-079), among others. In April 2025, Vera Therapeutics announced it had completed patient enrollment for its pivotal Phase III ORIGIN trial assessing atacicept in IgA nephropathy. The previous month, Otsuka Pharmaceutical submitted a Biologics License Application (BLA) to the FDA for sibeprenlimab, a monoclonal antibody aimed at inhibiting APRIL (A PRoliferation-Inducing Ligand) in adults with IgAN. Additionally, in July 2022, the European Commission granted Orphan Drug Designation (ODD) to BION-1301 for primary IgAN, offering regulatory benefits to support its European development. Strengthening its renal pipeline, Novartis acquired Chinook Therapeutics in August 2023 for up to $3.5 billion, adding zigakibart and other late-stage kidney-focused assets to its portfolio. To know how does FILSPARI compare to other treatments for IgA nephropathy, visit @ FILSPARI Approval Date Key Milestones of FILSPARI In November 2024, FILSPARI was approved by the MHRA for primary IgAN treatment, and sparsentan received approval in Germany for the same indication. In September 2024, the FDA granted full approval for FILSPARI to slow kidney function decline in IgAN patients, based on positive long-term results from the PROTECT Study. In April 2024, CSL Vifor and Travere Therapeutics received Conditional Marketing Authorization (CMA) from the European Commission for FILSPARI in the EU, targeting adults with IgAN and significant proteinuria. In February 2023, the US FDA granted accelerated approval to FILSPARI (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid progression, with priority review. Discover how FILSPARI is shaping the IgAN treatment landscape @ FILSPARI IgAN FILSPARI Market Dynamics FILSPARI, developed by Travere Therapeutics, represents a significant advancement in the treatment of IgA Nephropathy, a rare and chronic autoimmune kidney disease. Approved under the FDA's accelerated approval program in early 2023, FILSPARI is the first non-immunosuppressive therapy specifically targeting proteinuria in IgAN. It is a dual endothelin angiotensin receptor antagonist (DEARA), a novel mechanism that distinguishes it from conventional RAAS inhibitors. Its market entry has been notable for both its scientific innovation and potential to reshape the standard of care for IgAN, particularly in patients at high risk of progression to end-stage kidney disease (ESKD). The market dynamics are influenced by multiple factors, including the unmet need in IgAN, the orphan drug designation, and the limited competition in the space. Prior to FILSPARI's launch, treatment was largely supportive, focusing on blood pressure control and proteinuria reduction via ACE inhibitors or ARBs. FILSPARI's ability to deliver greater proteinuria reduction without the side effects associated with corticosteroids or immunosuppressants provides a compelling clinical and commercial value proposition. Competition is evolving, with several companies advancing novel IgAN therapeutics. Calliditas Therapeutics' TARPEYO (budesonide) was approved ahead of FILSPARI for a similar indication, but works through a corticosteroid pathway. Other players are also advancing programs, suggesting the market could become more segmented based on patient profile and mechanism of action. FILSPARI's differentiated profile, especially its dual-acting mechanism and oral administration, positions it favorably among nephrologists and specialists, but maintaining this edge will require strong real-world evidence and ongoing clinical data. From a market access and adoption standpoint, Travere has made early efforts in physician education, patient support programs, and collaboration with nephrology groups to accelerate uptake. However, broader adoption will depend on securing favorable formulary placements, long-term safety data, and sustained efficacy in delaying disease progression. As IgAN awareness grows and diagnosis rates improve through genetic and biomarker testing, the addressable patient population may expand, offering a significant growth opportunity for FILSPARI over the next 5–10 years. Dive deeper to get more insight into FILSPARI's strengths & weaknesses relative to competitors @ FILSPARI MoA Table of Contents 1 Report Introduction 2 FILSPARI: Travere Therapeutics 2.1 Product Overview 2.2 Other Development Activities 2.3 Clinical Development 2.4 Clinical Trials Information 2.5 Safety and Efficacy 2.6 Product Profile 2.7 Market Assessment 2.7.1 The 7MM Analysis 2.7.1.1 Cost Assumptions and Rebate 2.7.1.2 Pricing Trends 2.7.1.3 Analogue Assessment 2.7.1.4 Launch Year and Therapy Uptake 2.7.2 The United States Market Analysis 2.7.3 EU4 and the United Kingdom Market Analysis 2.7.3.1 Germany 2.7.3.2 France 2.7.3.3 Italy 2.7.3.4 Spain 2.7.3.5 UK 2.7.4 Japan Market Analysis 2.8 Market Drivers 2.9 Market Barriers 2.10 SWOT Analysis 3 Key Cross of Marketed Competitors of FILSPARI 4 Key Cross of Emerging Competitors of FILSPARI Related Reports IgA Nephropathy Market IgA Nephropathy Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key IgAN companies such as Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., among others. IgA Nephropathy Pipeline IgA Nephropathy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key IgA nephropathy companies, including Chinook Therapeutics, Inc., RemeGen Co., Ltd., Novartis, Jiangsu HengRui Medicine Co., Ltd., Ionis Pharmaceuticals, Inc., Vera Therapeutics, Inc., Eledon Pharmaceuticals, Guangdong Hengrui Pharmaceutical Co., Ltd, Omeros Corporation, Otsuka Pharmaceutical, Alnylam Pharmaceuticals, MorphoSys AG, Rohto Pharmaceutical, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Takeda, Travere Therapeutics, BioCryst Pharmaceuticals, Transcenta Holding, Shanghai Alebund Pharmaceuticals, DiaMedica Therapeutics, SELECTA BIOSCIENCES, Kira Pharmaceuticals, Alpine Immune Sciences, among others. Chronic Kidney Disease Market Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic kidney disease companies, including ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc, Lexicon Pharmaceuticals, Sanofi, among others. Chronic Kidney Disease Pipeline Chronic Kidney Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key chronic kidney disease companies, including KBP Biosciences, Eli Lilly and Company, Novo Nordisk, Prokidney, Boryung Pharmaceutical, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
FILSPARI to Transform Kidney Disease Care with Its Revolutionary Treatment Approach
FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers seek disease-modifying options, FILSPARI is well-positioned to capture substantial market share, especially with favorable long-term data. LAS VEGAS, May 27, 2025 /PRNewswire/ -- DelveInsight's "FILSPARI Market Size, Forecast, and Market Insight Report" highlights the details around FILSPARI, the first and only oral, once-daily, non-immunosuppressive therapy approved in both the US and Europe for IgAN. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of FILSPARI. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Travere Therapeutics' FILSPARI (sparsentan) Overview FILSPARI (sparsentan) is a once-daily oral treatment that uniquely targets two key pathways, endothelin-1 and angiotensin II (also known as DEARA), in the progression of IgA nephropathy. It is the first approved non-immunosuppressive therapy for this condition. Endothelin-1 and angiotensin II contribute to kidney function decline by promoting inflammation and fibrosis, altering podocyte structure, causing podocyte loss, and increasing the permeability of the glomerular filtration barrier. Additionally, both are vasoconstrictors that narrow blood vessels and raise pressure in the glomeruli. The drug received accelerated approval based on its ability to reduce proteinuria. Due to potential safety concerns, it is distributed under the FILSPARI Risk Evaluation and Mitigation Strategy (REMS) program. In Europe, it is marketed by CSL Vifor, and in Japan by Renalys Pharma. Results from the registration-enabling study are expected in the second half of 2025. Drug Name FILSPARI (sparsentan) Molecule type Small molecule Developer Travere Therapeutics Primary Indication Immunoglobulin A nephropathy FILSPARI MoA ETAR antagonist; AT1R antagonist Route of administration Oral Learn more about FILSPARI projected market size for IgAN @ FILSPARI IgA Nephropathy IgA nephropathy (IgAN) is an autoimmune disorder that disrupts kidney function by damaging the small blood vessels responsible for filtration. This damage is caused by an abnormal protein that harms the glomeruli, the kidneys' main filtering units. According to DelveInsight, there were approximately 415,000 diagnosed prevalent cases of IgAN across the seven major markets in 2024, and this number is projected to grow at a CAGR of 0.6% through 2034. Current standard care involves the use of ACE inhibitors and angiotensin II receptor blockers (ARBs), primarily to manage associated symptoms like hypertension. Currently, only a few drugs have been approved for IgAN treatment, including VANRAFIA (Atrasentan) and FABHALTA (Iptacopan) by Novartis, FILSPARI (Sparsentan) by Travere Therapeutics, and TARPEYO/KINPEYGO (budesonide) by Asahi Kasei (Calliditas Therapeutics), among others. The treatment landscape is expected to undergo major changes between 2024 and 2034, driven by the introduction of innovative therapies. DelveInsight estimates the IgAN market across the seven key regions was valued at around USD 730 million in 2024 and is projected to grow at a strong CAGR of 30.5% from 2025 to 2034. With targeted treatment options for IgAN only recently emerging and a pressing need for therapies that can delay progression to end-stage kidney disease (ESKD), significant advancements in this area are likely to profoundly reshape the market in the coming years. Discover more about the IgAN market in detail @ IgA Nephropathy Market Assessment Emerging Competitors of FILSPARI Key companies advancing therapies for IgA nephropathy include Novartis (Zigakibart/FUB523), F. Hoffmann-La Roche and Ionis Pharmaceuticals (Sefaxersen/RG6299/IONIS-FB-LRx), AstraZeneca's Alexion Pharmaceuticals (ULTOMIRIS), Vera Therapeutics (Atacicept), Vertex Pharmaceuticals (Povetacicept), Otsuka Pharmaceutical (Sibeprenlimab), Biogen (Felzartamab), Arrowhead Pharmaceuticals (ARO-C3), NovelMed (NM8074), Q32 Bio (ADX-097), Walden Biosciences (WAL0921), and Takeda Pharmaceutical (TAK-079), among others. In April 2025, Vera Therapeutics announced it had completed patient enrollment for its pivotal Phase III ORIGIN trial assessing atacicept in IgA nephropathy. The previous month, Otsuka Pharmaceutical submitted a Biologics License Application (BLA) to the FDA for sibeprenlimab, a monoclonal antibody aimed at inhibiting APRIL (A PRoliferation-Inducing Ligand) in adults with IgAN. Additionally, in July 2022, the European Commission granted Orphan Drug Designation (ODD) to BION-1301 for primary IgAN, offering regulatory benefits to support its European development. Strengthening its renal pipeline, Novartis acquired Chinook Therapeutics in August 2023 for up to $3.5 billion, adding zigakibart and other late-stage kidney-focused assets to its portfolio. To know how does FILSPARI compare to other treatments for IgA nephropathy, visit @ FILSPARI Approval Date Key Milestones of FILSPARI In November 2024, FILSPARI was approved by the MHRA for primary IgAN treatment, and sparsentan received approval in Germany for the same indication. In September 2024, the FDA granted full approval for FILSPARI to slow kidney function decline in IgAN patients, based on positive long-term results from the PROTECT Study. In April 2024, CSL Vifor and Travere Therapeutics received Conditional Marketing Authorization (CMA) from the European Commission for FILSPARI in the EU, targeting adults with IgAN and significant proteinuria. In February 2023, the US FDA granted accelerated approval to FILSPARI (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid progression, with priority review. Discover how FILSPARI is shaping the IgAN treatment landscape @ FILSPARI IgAN FILSPARI Market Dynamics FILSPARI, developed by Travere Therapeutics, represents a significant advancement in the treatment of IgA Nephropathy, a rare and chronic autoimmune kidney disease. Approved under the FDA's accelerated approval program in early 2023, FILSPARI is the first non-immunosuppressive therapy specifically targeting proteinuria in IgAN. It is a dual endothelin angiotensin receptor antagonist (DEARA), a novel mechanism that distinguishes it from conventional RAAS inhibitors. Its market entry has been notable for both its scientific innovation and potential to reshape the standard of care for IgAN, particularly in patients at high risk of progression to end-stage kidney disease (ESKD). The market dynamics are influenced by multiple factors, including the unmet need in IgAN, the orphan drug designation, and the limited competition in the space. Prior to FILSPARI's launch, treatment was largely supportive, focusing on blood pressure control and proteinuria reduction via ACE inhibitors or ARBs. FILSPARI's ability to deliver greater proteinuria reduction without the side effects associated with corticosteroids or immunosuppressants provides a compelling clinical and commercial value proposition. Competition is evolving, with several companies advancing novel IgAN therapeutics. Calliditas Therapeutics' TARPEYO (budesonide) was approved ahead of FILSPARI for a similar indication, but works through a corticosteroid pathway. Other players are also advancing programs, suggesting the market could become more segmented based on patient profile and mechanism of action. FILSPARI's differentiated profile, especially its dual-acting mechanism and oral administration, positions it favorably among nephrologists and specialists, but maintaining this edge will require strong real-world evidence and ongoing clinical data. From a market access and adoption standpoint, Travere has made early efforts in physician education, patient support programs, and collaboration with nephrology groups to accelerate uptake. However, broader adoption will depend on securing favorable formulary placements, long-term safety data, and sustained efficacy in delaying disease progression. As IgAN awareness grows and diagnosis rates improve through genetic and biomarker testing, the addressable patient population may expand, offering a significant growth opportunity for FILSPARI over the next 5–10 years. Dive deeper to get more insight into FILSPARI's strengths & weaknesses relative to competitors @ FILSPARI MoA Table of Contents 1 Report Introduction 2 FILSPARI: Travere Therapeutics 2.1 Product Overview 2.2 Other Development Activities 2.3 Clinical Development 2.4 Clinical Trials Information 2.5 Safety and Efficacy 2.6 Product Profile 2.7 Market Assessment 2.7.1 The 7MM Analysis 2.7.1.1 Cost Assumptions and Rebate 2.7.1.2 Pricing Trends 2.7.1.3 Analogue Assessment 2.7.1.4 Launch Year and Therapy Uptake 2.7.2 The United States Market Analysis 2.7.3 EU4 and the United Kingdom Market Analysis 2.7.3.1 Germany 2.7.3.2 France 2.7.3.3 Italy 2.7.3.4 Spain 2.7.3.5 UK 2.7.4 Japan Market Analysis 2.8 Market Drivers 2.9 Market Barriers 2.10 SWOT Analysis 3 Key Cross of Marketed Competitors of FILSPARI 4 Key Cross of Emerging Competitors of FILSPARI Related Reports IgA Nephropathy Market IgA Nephropathy Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key IgAN companies such as Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., among others. IgA Nephropathy Pipeline IgA Nephropathy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key IgA nephropathy companies, including Chinook Therapeutics, Inc., RemeGen Co., Ltd., Novartis, Jiangsu HengRui Medicine Co., Ltd., Ionis Pharmaceuticals, Inc., Vera Therapeutics, Inc., Eledon Pharmaceuticals, Guangdong Hengrui Pharmaceutical Co., Ltd, Omeros Corporation, Otsuka Pharmaceutical, Alnylam Pharmaceuticals, MorphoSys AG, Rohto Pharmaceutical, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Takeda, Travere Therapeutics, BioCryst Pharmaceuticals, Transcenta Holding, Shanghai Alebund Pharmaceuticals, DiaMedica Therapeutics, SELECTA BIOSCIENCES, Kira Pharmaceuticals, Alpine Immune Sciences, among others. Chronic Kidney Disease Market Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic kidney disease companies, including ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc, Lexicon Pharmaceuticals, Sanofi, among others. Chronic Kidney Disease Pipeline Chronic Kidney Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key chronic kidney disease companies, including KBP Biosciences, Eli Lilly and Company, Novo Nordisk, Prokidney, Boryung Pharmaceutical, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hadat Com
4 days ago
- Health
- Hadat Com
المجلس الأعلى للحسابات يصدر تقريره السنوي رسم سنة 2023 المتعلق بتدقيق حسابات الأحزاب السياسية
The Key Molybdenum cofactor deficiency type A Companies in the market include – Bridge Biopharma, Origin Biosciences, and others. DelveInsight's 'Molybdenum cofactor deficiency type A Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Molybdenum cofactor deficiency type A, historical and forecasted epidemiology as well as the Molybdenum cofactor deficiency type A market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Molybdenum cofactor deficiency type A market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Molybdenum cofactor deficiency type A Market Forecast Some of the key facts of the Molybdenum cofactor deficiency type A Market Report: The Molybdenum cofactor deficiency type A market size was valued approximately USD 12 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In April 2025, Sentynl Therapeutics, Inc. ('Sentynl'), a U.S.-based biopharmaceutical company fully owned by Zydus Lifesciences, Ltd. ('Zydus Group'), announced the publication of three clinical studies on NULIBRY in the Journal of Inherited Metabolic Disease. These studies compare the treatment outcomes of NULIBRY to a natural history study. Fosdenopterin, the active ingredient in NULIBRY, received regulatory approvals from the U.S. FDA in February 2021, the Israeli Ministry of Health (MoH) in July 2022, the European Medicines Agency (EMA) in September 2022, and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2024 for treating MoCD Type A. Among the 7MM countries, the United States led the market in 2023, accounting for almost 68% of the total share. In 2023, the EU4 and the UK generated an estimated USD 3.9 million, with this figure expected to grow at a strong CAGR. Within Europe, Germany and France held the largest market shares that year, followed by the UK and Italy, while Spain represented the smallest portion of the market. DelveInsight's analysts estimate that around 270 prevalent cases of MOCOD-A were identified in the 7MM in 2023. The United States reported the highest number of diagnosed prevalent MOCOD-A cases compared to the other 7MM countries. According to DelveInsight's estimates, there were approximately 30 diagnosed prevalent cases of MOCOD-A in the US in 2023, and this number is expected to rise over the forecast period due to growing awareness among patients. DelveInsight's estimates indicate that the total diagnosed prevalent cases of MOCOD-A in the EU4 and the UK were approximately 20 in 2023. Over the course of the study period, a notable rise in cases is expected across all contributing countries. Among the EU4 nations, Spain reported the lowest share of MOCOD-A cases. The data shows that Japan recorded the fewest total diagnosed prevalent cases of MOCOD-A among the 7MM in 2023, representing only 9% of the total cases. However, it is expected to see significant growth by 2034, marked by a notable CAGR. Key Molybdenum cofactor deficiency type A Companies: Bridge Biopharma, Origin Biosciences, and others Key Molybdenum cofactor deficiency type A Therapies: Nulibry, ORGN001 (formerly ALXN1101), and others The Molybdenum cofactor deficiency type A epidemiology based on gender analyzed that MoCoD-A affects both gender equally The Molybdenum cofactor deficiency type A market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Molybdenum cofactor deficiency type A pipeline products will significantly revolutionize the Molybdenum cofactor deficiency type A market dynamics. Molybdenum cofactor deficiency type A Overview A severe autosomal recessive inborn metabolic mistake called molybdenum cofactor deficiency (MoCoD-A) is characterized by neonatal persistent seizures, feeding issues, developmental delays, microcephaly with brain shrinkage, and coarse facial features. Get a Free sample for the Molybdenum cofactor deficiency type A Market Report: Molybdenum cofactor deficiency type A Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Molybdenum cofactor deficiency type A Epidemiology Segmentation: The Molybdenum cofactor deficiency type A market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalence of Molybdenum cofactor deficiency type A Prevalent Cases of Molybdenum cofactor deficiency type A by severity Gender-specific Prevalence of Molybdenum cofactor deficiency type A Diagnosed Cases of Episodic and Chronic Molybdenum cofactor deficiency type A Download the report to understand which factors are driving Molybdenum cofactor deficiency type A epidemiology trends @ Molybdenum cofactor deficiency type A Epidemiology Forecast Molybdenum cofactor deficiency type A Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Molybdenum cofactor deficiency type A market or expected to get launched during the study period. The analysis covers Molybdenum cofactor deficiency type A market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Molybdenum cofactor deficiency type A Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Molybdenum cofactor deficiency type A Therapies and Key Companies Nulibry: Bridge Biopharma ORGN001 (formerly ALXN1101): Origin Biosciences Discover more about therapies set to grab major Molybdenum cofactor deficiency type A market share @ Molybdenum cofactor deficiency type A Treatment Market Molybdenum cofactor deficiency type A Market Drivers Large untapped market Shortcomings associated with current treatment Overall increase in seizure related diagnosis Molybdenum cofactor deficiency type A Market Barriers Highly undiagnosed condition Problems associated with conducting clinical studies Need for a comprehensive rapid precision medicine system Scope of the Molybdenum cofactor deficiency type A Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Molybdenum cofactor deficiency type A Companies: Bridge Biopharma, Origin Biosciences, and others Key Molybdenum cofactor deficiency type A Therapies: Nulibry, ORGN001 (formerly ALXN1101), and others Molybdenum cofactor deficiency type A Therapeutic Assessment: Molybdenum cofactor deficiency type A current marketed and Molybdenum cofactor deficiency type A emerging therapies Molybdenum cofactor deficiency type A Market Dynamics: Molybdenum cofactor deficiency type A market drivers and Molybdenum cofactor deficiency type A market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Molybdenum cofactor deficiency type A Unmet Needs, KOL's views, Analyst's views, Molybdenum cofactor deficiency type A Market Access and Reimbursement To know more about Molybdenum cofactor deficiency type A companies working in the treatment market, visit @ Molybdenum cofactor deficiency type A Clinical Trials and Therapeutic Assessment Table of Contents 1. Molybdenum cofactor deficiency type A Market Report Introduction 2. Executive Summary for Molybdenum cofactor deficiency type A 3. SWOT analysis of Molybdenum cofactor deficiency type A 4. Molybdenum cofactor deficiency type A Patient Share (%) Overview at a Glance 5. Molybdenum cofactor deficiency type A Market Overview at a Glance 6. Molybdenum cofactor deficiency type A Disease Background and Overview 7. Molybdenum cofactor deficiency type A Epidemiology and Patient Population 8. Country-Specific Patient Population of Molybdenum cofactor deficiency type A 9. Molybdenum cofactor deficiency type A Current Treatment and Medical Practices 10. Molybdenum cofactor deficiency type A Unmet Needs 11. Molybdenum cofactor deficiency type A Emerging Therapies 12. Molybdenum cofactor deficiency type A Market Outlook 13. Country-Wise Molybdenum cofactor deficiency type A Market Analysis (2020–2034) 14. Molybdenum cofactor deficiency type A Market Access and Reimbursement of Therapies 15. Molybdenum cofactor deficiency type A Market Drivers 16. Molybdenum cofactor deficiency type A Market Barriers 17. Molybdenum cofactor deficiency type A Appendix 18. Molybdenum cofactor deficiency type A Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
